Cost Effectiveness of Eplerenone in Patients with Heart Failure after Acute Myocardial Infarction Who were Taking Both ACE Inhibitors and β-Blockers: Subanalysis of the EPHESUS

School of Public Health, Nantong University, Nantong, P.R. China.
American Journal of Cardiovascular Drugs (Impact Factor: 2.42). 02/2010; 10(1):55-63. DOI: 10.2165/11319940-000000000-00000
Source: PubMed


The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure and Survival Study) showed that the use of aldosterone blockade with eplerenone decreased mortality in patients with heart failure after acute myocardial infarction, and a subsequent analysis showed eplerenone to be highly cost effective in this population.
To assess the cost effectiveness of eplerenone in an EPHESUS subgroup population who were taking both ACE inhibitors and beta-blockers (beta-adrenoceptor antagonists) at baseline. In the EPHESUS, a total of 6632 patients were randomized to receive eplerenone 25-50 mg/day (n = 3319) or placebo (n = 3313) concurrently with standard therapy and were followed for up to 2.5 years. Of these, 4265 (64.3%) patients (eplerenone: n = 2113; placebo: n = 2152) were taking both ACE inhibitors and beta-blockers at baseline.
Resource use after the initial hospitalization included additional hospitalizations, outpatient services, emergency room visits, and medications. Eplerenone was priced at an average wholesale price of $US3.60 per day (year 2004 value). Bootstrap methods were used to estimate the fraction of the joint distribution of the cost and effectiveness. A net-benefit regression model was used to derive the propensity score-adjusted cost-effectiveness curve. The incremental cost effectiveness of eplerenone in cost per life-year gained (LYG) and cost per quality-adjusted life-year (QALY) gained beyond the trial period was estimated using data from the Framingham Heart Study, the Saskatchewan Health database, and the Worcester Heart Attack Registry. Both costs and effectiveness were discounted at 3%. Although not all resource use could be accounted for, the overall perspective was societal.
As in the overall EPHESUS population, the total direct treatment costs were higher in the eplerenone arm than the placebo arm for patients who were taking both ACE inhibitors and beta-blockers ($US14,563 vs $US12,850, difference = $US1713; 95% CI 721, 2684). The number of LYGs with eplerenone compared with placebo was 0.1665 based on the Framingham data, 0.0979 using the Saskatchewan data, and 0.2172 using the Worcester data. The incremental cost-effectiveness ratio (ICER) was $US10,288/LYG with the Framingham data, $US17,506/LYG with the Saskatchewan data, and $US7888/LYG with the Worcester data (99% <$US50,000/LYG for all three sources). The ICERs were systematically higher when calculated as the cost per QALY gained ($US14,926, $US25,447, and $US11,393, respectively) as the utilities were below 1 with no difference between the treatment arms.
As for the overall EPHESUS population, aldosterone blockade with eplerenone is effective in reducing mortality and is cost effective in increasing years of life for the EPHESUS subgroup of patients who were taking both ACE inhibitors and beta-blockers.

16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents a unified framework for the use of neural networks for the modelling and control of unknown nonlinear systems. The systems are assumed to be expressed by a unknown NARMA model including a set of unknown parameters. At first, it is assumed that the nominal (initial) values of these parameters are known during an initial operation period of the system. By incorporating the nominal parameter set into the structure of neural network, a neural network model for the system can be established via online training of the weights during the initial operation period. Using the trained neural network, the estimation of the parameters is achieved by incorporating the estimated parameters into the neural network model and by constructing a gradient descent based estimation algorithm. The design of the controllers for the unknown nonlinear systems have been discussed and desired results have been obtained via comparing existing neural network based modelling approaches
    Neural Networks, 1996., IEEE International Conference on; 07/1996
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Based on our detailed theoretical analysis we fabricated 1D Si/SiO <sub>2</sub> photonic crystals with donor and acceptor defects. We observed their photonic band-gaps and defect modes by measuring the infrared transmission of the samples. We propose here the application of this type of structure for enhancement of InSb photodetector detectivity
    Microelectronics, 1997. Proceedings., 1997 21st International Conference on; 10/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this article, we review the evidence supporting the use of eplerenone for improving cardiovascular prognosis. Activation of the renin-angiotensin-aldosterone system plays a major role in the pathogenesis of heart disease, and blockage of this system has been shown to improve prognosis in several cardiovascular conditions. The 2 marketed aldosterone antagonists, spironolactone and eplerenone, improve prognosis in patients with left ventricular (LV) dysfunction and are effective antihypertensive medications. In addition, a potential role for aldosterone antagonists in the treatment of patients with heart failure and preserved LV function has been suggested and is currently being evaluated in clinical trials. In patients with myocardial infarction having LV dysfunction and evidence of heart failure, eplerenone improves cardiovascular outcomes and attenuates myocardial remodeling. In addition, eplerenone is effective for the treatment of hypertension, where it regresses both LV hypertrophy and proteinuria (2 powerful markers of increased cardiovascular risk). In contrast to spironolactone, eplerenone essentially lacks the sexual side effects that sometimes limit the use of spironolactone. Hyperkalemia is the main potential side effect of eplerenone, especially when used in combination with other medications that can cause hyperkalemia. Adequate patient selection and monitoring are therefore of utmost importance when using this medication. In conclusion, eplerenone is a medication that offers the cardiovascular therapeutic and prognostic benefits of aldosterone antagonism but with fewer side effects compared to spironolactone.
    Journal of Cardiovascular Pharmacology and Therapeutics 09/2010; 15(4):318-25. DOI:10.1177/1074248410371946 · 2.09 Impact Factor
Show more